BioCryst

YTD

ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

CEO

Charles K. Gayer

CEOCharles K. Gayer

Employees

435

Employees435

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

1986

Founded1986

Employees

435

Employees435

BCRX Key Statistics

Market cap

2.53B

Market cap2.53B

Price-Earnings ratio

-6.24

Price-Earnings ratio-6.24

Dividend yield

—

Dividend yield—

Average volume

3.53M

Average volume3.53M

High today

$9.67

High today$9.67

Low today

$9.24

Low today$9.24

Open price

$9.50

Open price$9.50

Volume

4.38M

Volume4.38M

52 Week high

$11.22

52 Week high$11.22

52 Week low

$6.00

52 Week low$6.00

Stock Snapshot

With a market cap of 2.53B, BioCryst(BCRX) trades at $9.42. The stock has a price-to-earnings ratio of -6.24.

During the trading session on 2026-08-10, BioCryst(BCRX) shares reached a daily high of $9.67 and a low of $9.24. At a current price of $9.42, the stock is +2.0% higher than the low and still -2.5% under the high.

Trading activity shows a volume of 4.38M, compared to an average daily volume of 3.53M.

The stock's 52-week range extends from a low of $6.00 to a high of $11.22.

BCRX News

Simply Wall St 3d

How BioCryst’s Higher 2026 Revenue Guidance and Mixed Earnings Picture Will Impact BioCryst Pharmaceuticals Investors

In August 2026, BioCryst Pharmaceuticals reported second-quarter 2026 results showing revenue of US$218.25 million and net income of US$78.40 million, alongside...

TipRanks 4d

BioCryst price target lowered to $13 from $14 at RBC Capital

RBC Capital analyst Brian Abrahams lowered the firm’s price target on BioCryst (BCRX) to $13 from $14 and keeps an Outperform rating on the shares. BioCryst rep...

TipRanks 4d

Stacy Ku Reiterates Buy on BioCryst, Citing Strong Orladeyo Momentum, Durable Growth, and Billion-Dollar HAE Opportunities

BioCryst, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stacy Ku from TD Cowen maintained a Buy rating on the stock a...

Analyst ratings

91%

of 11 ratings

Buy

90.9%

Hold

9.1%

Sell

More BCRX News

TipRanks 5d

BioCryst Reports Strong Q2 Results, Raises 2026 Guidance

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 6d

BioCryst Pharmaceuticals Faces A Valuation Test, Is The Undervalued Case Convincing?

BioCryst Pharmaceuticals (BCRX) stock has been under pressure recently, with the share price down about 10% over the past month and roughly flat over the past 3...

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.